CANTON, Mass., May 23, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:
- The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m. ET in New York City
- The 37th Annual William Blair Growth Stock Conference on Wednesday, June 14th at 2:40 p.m. CT at The Four Seasons Hotel Chicago
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla adasalla@collegiumpharma.com
